Endo News Roundup: Diabetes and Cardiovascular Disease

March 30, 2017

Studies include drug-free remission of T2DM, and the impact of hyperglycemia and hypoglycemia on cardiovascular health.

Three new studies on T2DM highlight a combination of intensive lifestyle change and drug therapy and the risks of both hyperglycemia and hypoglycemia. T2DM patients who maintain a short course of intensive lifestyle and drug therapy that reduces weight and controls blood glucose may be able to enjoy several months of drug-free remission; a large population study that followed T2DM patients from diagnosis shows hyperglycemia remains as an essential risk factor for heart failure, as has been demonstrated in earlier studies; and on the other side of the coin, hypoglycemia risk is an indicator for cardiovascular disease (CVD) and death in older adults with T2DM.

Endocrinology News Roundup: Diabetes and Cardiovascular Disease. April 2017

Drug-Free Remission of T2DM Abstract link.

A short course of intensive lifestyle and drug therapy that leads to normal blood glucose levels and sustained weight loss may also induce prolonged, drug-free remission of T2DM.

A combination of intensive lifestyle and drug interventions may offer the promise of remission of T2DM.

Hyperglycemia Can Lead to Heart Failure Abstract link.

Hyperglycemia remains a strong risk factor for heart failure patients with T2DM.

Good glycemic control is essential in preventing heart failure in those with T2DM, and early as well as overall control is essential.

Hypoglycemia May Indicate CVD in T2DM Abstract link.

Severe hypoglycemia is associated with CVD and all-cause mortality in older adults with T2DM.

Severe hypoglycemia may influence CVD risk and death independently of diabetes severity and general vulnerability.

Clinical Implications

Related Content:

Endo News Roundup: Diabetes and Cardiovascular Disease

Mark L. Fuerst